צמיחת רווחי EPS רבעונית: Aethlon Medical (AEMD)

Steady demand for blood purification systems ensures the systematic expansion of the Aethlon Medical (AEMD) client base. The quarterly EPS change illustrates this trend, where 86.20 represents the latest level. Growth is supported by the development of the Hemopurifier biofilter designed to combat oncoexosomes. The technology for real-time physical removal of pathogens makes the device indispensable for treating critical infections.

For Aethlon Medical (AEMD), which holds a monopoly on high-tech hemopurification, the quarterly EPS growth rate serves as an indicator of how effectively the company monetizes its unique filters within the emergency medicine segment. This metric reflects the percentage change in net income per share compared to the same period last year, allowing investors to promptly assess business scaling rates and the market value of capital.